Unternehmensübersicht
BillionToOne, Inc. operates as a precision diagnostics company that quantifies biological systems to develop advanced molecular diagnostics for disease detection. The firm specializes in a molecular counting platform engineered to detect and measure DNA molecules at the single-count level, alongside its UNITY Complete offering. This entity functions within the Healthcare sector, specifically targeting the Diagnostics & Research industry, where it leverages technology to provide critical diagnostic solutions. With a market capitalization of $3.20 billion and annual revenue reaching $305.11 million, the company demonstrates significant scale supported by a workforce of 713 employees. These valuation and revenue figures position BillionToOne as a substantial player in the diagnostic market, reflecting a high market consensus on its potential while indicating a capitalization well above the average for early-stage biotechnology firms.
Finanzielle Gesundheit
BillionToOne reported trailing twelve-month revenue of $305.11 million, net income of $2.92 million, and EBITDA of $22.93 million for the most recent period. The substantial disparity between the $305.11 million in revenue and the $2.92 million in net income highlights a cost structure where operating expenses significantly impact the bottom line, resulting in a thin profit margin. The company generated $20.81 million in free cash flow, which provides a robust buffer for financial flexibility, capital expenditure, and potential strategic acquisitions. The gross margin stands at 68.3%, indicating efficient production or service delivery costs relative to sales, while the operating margin of 10.8% and profit margin of 1.0% reflect the high fixed cost environment typical of the research and diagnostics sector. On the balance sheet, the company holds $495.98 million in cash against $108.89 million in debt, supported by a debt-to-equity ratio of 22.68, suggesting a highly conservative capital structure with substantial liquidity reserves. The current ratio of 11.69 further confirms exceptional short-term liquidity, ensuring the ability to meet obligations well beyond standard operational needs. Return on Equity is calculated at 2.3% and Return on Assets at 2.1%, metrics that reveal the current return on invested capital is relatively modest, which is often characteristic of companies investing heavily in research and development or facing transitional earnings phases.
Bewertungsanalyse
The trailing twelve-month P/E ratio is 496.79, while the forward P/E is projected at 77.71, a difference that implies the market expects a significant increase in earnings per share to justify the multiple in the coming years. The price-to-book ratio stands at 6.64, indicating that the market values the company at a substantial premium over its tangible book value, likely due to intangible assets such as intellectual property and growth potential. Alternative valuation metrics include a price-to-sales ratio of 10.48 and an EV/EBITDA of 122.52, figures that suggest the stock is priced aggressively relative to its sales and earnings power. Regarding price action, the stock reached a 52-week high of $138.70 and a 52-week low of $61.96, meaning the current trading price fluctuates within a range that reflects high volatility but also significant upside potential from recent lows. The beta value is listed as N/A, which prevents a direct comparison of price volatility relative to the broader market index, though the wide spread between the 52-week high and low inherently suggests high sensitivity to market sentiment.
Growth & Income
Revenue growth year-over-year has accelerated to 113.1%, driven by the expansion of its molecular counting platform and UNITY Complete adoption in clinical settings. Earnings growth is currently N/A, indicating that while top-line revenue is expanding rapidly, the bottom-line profitability has not yet achieved a consistent growth trajectory to be quantified in standard percentage terms for the recent period. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that all earnings are retained to fuel further research, development, and market expansion rather than being distributed to shareholders. This reinvestment strategy aligns with the lifecycle of a diagnostics company focused on technological advancement and market penetration. Consequently, the overall growth and income profile is characterized by explosive top-line expansion and a total return strategy reliant on capital appreciation rather than dividend income, suitable for investors seeking exposure to high-growth healthcare innovation.